Clinical Trial

Study of Remimazolam for Cataract Surgery

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if the use of the sedative remimazolam improves the safety of patients having cataract surgery by decreasing the number of sedation-related complications during and after surgery, and shortening post-surgical cognitive recovery time.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-01-31 -> 2028-01-01 2026-04-30
minor Completion pushed: 2027-12-01 -> 2028-06-01 2026-04-30
Trial Details
NCT Number NCT07325227
Lead Sponsor Fred E, Shapiro
Collaborators: Eagle Pharmaceuticals, Inc., Massachusetts Eye and Ear Infirmary
Conditions Cataract Surgery Anesthesia
Enrollment 30 participants
Start Date 2026-09-15
Primary Completion 2028-01-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-15